Pavlos C Englezou is a Post-doctoral Scientist in the Immunology Department at the Institute of Virology and Immunology in Mittelhäusern, Switzerland who has joined the group of Dr. Kenneth C. McCullough since 2013 and is working as part of the European UNIVAX consortium. He completed his PhD at the University of Manchester in the UK. His research interests lie in the development of novel vaccination strategies using nanotechnology. More specifically his work examines the capacity of cationic lipids to deliver self-replicating RNA to porcine dendritic cells as part of a new vaccination strategy against Influenza A viruses. Pavlos C Englezou is a Post-doctoral Scientist in the Immunology Department at the Institute of Virology and Immunology in Mittelhäusern, Switzerland who has joined the group of Dr. Kenneth C. McCullough since 2013 and is working as part of the European UNIVAX consortium. He completed his PhD at the University of Manchester in the UK. His research interests lie in the development of novel vaccination strategies using nanotechnology. More specifically his work examines the capacity of cationic lipids to deliver self-replicating RNA to porcine dendritic cells as part of a new vaccination strategy against Influenza A viruses.

Vaccine, Immunology